D.E. Shaw & Co
ALXN

D.E. Shaw & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

D.E. Shaw & Co’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-20,900
Closed -$2.83M – 3968
2019
Q1 		$2.83M Buy
20,900
+10,000
+92% +$1.24M ﹤0.01% 1925
2018
Q4 		$1.06M Buy
+10,900
New +$1.29M ﹤0.01% 2613
2018
Q1 		– Sell
-15,000
Closed -$1.79M – 3879
2017
Q4 		$1.79M Buy
+15,000
New +$1.83M ﹤0.01% 2215
2016
Q1 		– Sell
-49,300
Closed -$9.4M – 3894
2015
Q4 		$9.4M Hold
49,300
– – 0.01% 999
2015
Q3 		$7.71M Hold
49,300
– – 0.01% 1119
2015
Q2 		$8.91M Hold
49,300
– – 0.01% 1085
2015
Q1 		$8.54M Sell
49,300
-24,400
-33% -$4.42M 0.01% 1063
2014
Q4 		$13.6M Sell
73,700
-38,200
-34% -$7.08M 0.02% 913
2014
Q3 		$18.6M Sell
111,900
-1,600
-1% -$263K 0.02% 741
2014
Q2 		$17.7M Buy
113,500
+4,200
+4% +$663K 0.02% 759
2014
Q1 		$16.6M Buy
109,300
+9,700
+10% +$1.54M 0.02% 750
2013
Q4 		$13.3M Buy
99,600
+37,100
+59% +$4.45M 0.02% 934
2013
Q3 		$7.26M Buy
62,500
+40,000
+178% +$4.39M 0.01% 1276
2013
Q2 		$2.08M Buy
+22,500
New +$2.17M ﹤0.01% 2075

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

D.E. Shaw & Co's ALXN Position: Q3 2021 in Review

D.E. Shaw & Co sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,241,928 shares — an estimated $228M sold.

D.E. Shaw & Co first reported a position in ALXN in Q2 2013 and held it in 30 quarters. The position peaked at $228M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • D.E. Shaw & Co reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,241,928 Alexion Pharmaceuticals shares in Q3 2021, an estimated $228M.
  • D.E. Shaw & Co first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 30 quarters.
  • D.E. Shaw & Co's Alexion Pharmaceuticals position peaked at $228M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.